This study evaluated whether the Vigor 2020, a new vacuum erection device (VED), is effective for the management of erectile dysfunction (ED). The main finding was that Vigor 2020 was effective for men with ED. 

This study reviewed the effectiveness and safety of L-arginine and Pycnogenol^® (PAL) in the treatment of male erectile dysfunction (ED). The data showed that the combination of PAL had a significant effect on improving sexual function in patients with mild to moderate ED.

This study reported the long-term effectiveness and safety of enzalutamide (Xtandi) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). The data showed that enzalutamide in combination with ADT improved the overall survival over the long term with manageable side effects in these patients.

This study investigated the effectiveness of RestoreX on penile length and erectile function in patients after prostate surgery. The data showed that RestoreX treatment improves penile length and erectile function in men who underwent prostate surgery.

The study evaluated the long-term effectiveness and safety outcomes of adding abiraterone acetate (AA; Zytiga) and prednisolone (P; Deltasone) with or without enzalutamide (Xtandi) in patients with metastatic prostate cancer (PC) starting androgen-deprivation therapy (ADT). The data showed that enzalutamide and AA+P should not be combined for patients with metastatic PC starting long-term ADT. Clinically important improvements in survival from the addition of AA+P to ADT can be maintained for longer than 7 years.

This study evaluated the association between statin (cholesterol-lowering drugs) use and survival outcomes in men with advanced prostate cancer (PC) undergoing androgen deprivation therapy (ADT). The data showed that statin use improved the survival outcomes in these patients.

This study evaluated the effectiveness and safety of platelet-rich plasma (PRP) injections for the treatment of patients with mild and moderate erectile dysfunction (ED). The data showed that PRP was a safe and promising treatment for improving mild to moderate ED.

This study evaluated the effectiveness and safety of Quisqualis indica (Rangoon creeper or Chinese honeysuckle; a type of plant) extract for the treatment of patients with lower urinary tract symptoms (LUTS). The data showed that Quisqualis indica extract was safe and effective for the treatment of these patients.

This study evaluated the outcomes of single-pass versus multiple-pass during aquablation in patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). The data showed that treatment with multiple passes during aquablation improved the urinary outcomes compared to a single pass in these patients.

This study evaluated the bone mineral density (BMD) screening rates and their association with fracture rates among older men with prostate cancer (PC) receiving androgen deprivation therapy (ADT). The data showed that BMD screening is associated with a lower major fracture risk in these patients.